
Nasir Mohajel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1860766/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Severe acute respiratory syndromeâ€coronavirusâ€2 spike (S) protein based vaccine candidates: State of the art and future prospects. Reviews in Medical Virology, 2021, 31, e2183.	8.3	43
2	Novel Descriptors Derived from the Aggregation Propensity of Di- and Tripeptides Can Predict the Critical Aggregation Concentration of Longer Peptides. ACS Omega, 2021, 6, 13331-13340.	3.5	2
3	Ebola as a case study for the patent landscape of medical countermeasures for emerging infectious diseases. Nature Biotechnology, 2021, 39, 799-807.	17.5	0
4	Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy. International Immunopharmacology, 2021, 96, 107762.	3.8	1
5	Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model. International Immunopharmacology, 2021, 101, 108298.	3.8	3
6	Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in E. Coli for Cancer Immunotherapy. Reports of Biochemistry and Molecular Biology, 2020, 9, 50-57.	1.4	2
7	Computational simulations assessment of mutations impact on streptokinase (SK) from a group G <i>streptococci</i> with enhanced activity – insights into the functional roles of structural dynamics flexibility of SK and stabilization of SK–I¼plasmin catalytic complex. Journal of Biomolecular Structure and Dynamics. 2019. 37. 1944-1955.	3.5	6
8	Rotavirus VP6 as a potential vaccine candidate. Reviews in Medical Virology, 2019, 29, e2027.	8.3	20
9	Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches. Journal of Cellular Physiology, 2019, 234, 8636-8646.	4.1	58
10	Immunization of Mice by Rotavirus NSP4-VP6 Fusion Protein Elicited Stronger Responses Compared to VP6 Alone. Viral Immunology, 2018, 31, 233-241.	1.3	8
11	Merkel cell polyomavirus IgG antibody levels are associated with progression to AIDS among HIV-infected individuals. Archives of Virology, 2017, 162, 963-969.	2.1	7
12	Interleukin 20 Gene Polymorphism (rs1518108) is not Associated with Sustained Virological Response in Iranian Patients with Hepatitis C Virus Infection. Clinical Laboratory, 2017, 63, 1431-1437.	0.5	1
13	Sindbis Virus-Pseudotyped Lentiviral Vectors Carrying VEGFR2-Specific Nanobody for Potential Transductional Targeting of Tumor Vasculature. Molecular Biotechnology, 2016, 58, 738-747.	2.4	16
14	Diversity of VP7 genes of G1 rotaviruses isolated in Iran, 2009–2013. Infection, Genetics and Evolution, 2016, 37, 275-279.	2.3	3
15	Inhaled sildenafil nanocomposites: lung accumulation and pulmonary pharmacokinetics. Pharmaceutical Development and Technology, 2016, 21, 961-971.	2.4	14
16	Prevalence of Merkel Cell Polyomavirus in Tehran: An Age-Specific Serological Study. Iranian Red Crescent Medical Journal, 2016, 18, e26097.	0.5	10
17	Expression of HCV Alternative Reading Frame Protein (Core+1/F) in Baculovirus Expression System and its Evaluation for Assessment of Specific Anti-core+1 Antibody in Iranian HCV Infected Patients. Clinical Laboratory, 2016, 62, 1919-1926.	0.5	1
18	Correlation Study Between IL-28B Gene Polymorphism (rs8099917SNP) and Sustained Virological Response in Iranian Patients with Chronic Hepatitis C. Clinical Laboratory, 2016, 62, 417-23.	0.5	4

NASIR MOHAJEL

#	Article	IF	CITATIONS
19	Lack of TNF-α Gene Polymorphism (rs1799724) Association with Sustained Virological Response in Iranian Patients with Chronic HCV Infection. Asian Pacific Journal of Cancer Prevention, 2016, 17, 3923-7.	1.2	1
20	Expression of a biotin acceptor peptide-containing protein with potential incorporation on the lentiviral envelope as a viral surface engineering platform. Research in Pharmaceutical Sciences, 2015, 10, 268-74.	1.8	1
21	Drying of a plasmid containing formulation: chitosan as a protecting agent. DARU, Journal of Pharmaceutical Sciences, 2012, 20, 22.	2.0	7
22	Preparation and evaluation of inhalable itraconazole chitosan based polymeric micelles. DARU, Journal of Pharmaceutical Sciences, 2012, 20, 85.	2.0	28
23	Optimization of a spray drying process to prepare dry powder microparticles containing plasmid nanocomplex. International Journal of Pharmaceutics, 2012, 423, 577-585.	5.2	37
24	Development of chitosan-based nanoparticles for pulmonary delivery of itraconazole as dry powder formulation. Powder Technology, 2012, 222, 65-70.	4.2	75